Key facts
- FerroptoCure’s last known valuation is $10.2M (Mar 2023).
- It has raised $7.3M; the latest was Early Stage VC ($3.1M) in Sep 2025.
- Notable investors include ANRI, Japan External Trade Organization, FASTAR, Tokyo University of Science Investment Management, Keio University — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for FerroptoCure
- ·The full record, as it builds
Funding rounds
No funding rounds for FerroptoCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FerroptoCure
Developer of therapeutic drugs designed to develop anticancer therapies based on scientific evidence. The company has created an anticancer drug that utilizes ferroptosis, next-generation sequencing, data informatics, and silico analysis, enabling patients with cancer to get a proper cure and treatment.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Employees
- 10
- Website
- ferroptocure.com/
- Ownership
- Privately Held (backing)
FerroptoCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FerroptoCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FerroptoCure in its N-PORT filings yet. We sweep new filings monthly.